Relay Therapeutics (RLAY) Pullback Puts Its Vascular Anomalies Valuation Narrative To The Test
Relay Therapeutics Stock Performance Snapshot
Relay Therapeutics (RLAY) has drawn investor attention after recent price moves, with the shares last closing at US$17.95. The stock has declined over the past week, month, and past 3 months, yet remains strongly positive year to date and over the past year.
Recent trading has cooled, with the share price return down 4.2% over the last day and 13.5% over the past 3 months. Even so, Relay Therapeutics still shows strong positive momentum when you zoom out, supported by a 119.4% year to date share price return and a 193.8% 1 year total shareholder return.
Scan beyond Relay Therapeutics and explore other fast-moving healthcare ideas with the hand-picked 34 healthcare AI stocks that are catching market attention right now.
The recent surge in Relay Therapeutics followed by a sharp pullback raises a simple question. Are traders just resetting sentiment after a hot run, or has the share price moved closer to what the business itself supports?
Most Popular Narrative: 35% Undervalued
Relay Therapeutics is trading at $17.95 against a most-followed fair value estimate of about $27.58. The current pullback still sits well below that narrative anchor while the story leans heavily on late stage oncology and vascular anomaly programs.
Advance of zovegalisib in PI3Kα driven vascular anomalies through the ReInspire study, including expansion cohorts at a once daily 400 mg dose and upcoming FDA discussions on a possible single arm accelerated approval path pooling PROS and lymphatic malformations, targets an estimated 25,000 addressable US patients within a US$6b to US$8b total addressable market. This could create a chronic high price branded revenue stream with attractive gross margins.
See why 1 investors see Relay Therapeutics as 35% undervalued.
Result: Fair Value of $27.58 (UNDERVALUED)
Still, if zovegalisib stumbles in Phase 3 breast cancer trials or if regulators push back on the vascular anomalies path, the Relay Therapeutics story could change quickly.
Find out about the key risks to this Relay Therapeutics narrative.
Next Steps
Conflicted about whether the recent enthusiasm around Relay Therapeutics still holds up after the pullback? Move quickly, review the full picture, and weigh both sides of the story with the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Relay Therapeutics?
If the Relay Therapeutics story has you thinking bigger about your portfolio, use this moment to broaden your watchlist with fresh, data driven opportunities.
- Hunt for potential mispriced opportunities by zeroing in on companies flagged as 29 high quality undervalued stocks before the crowd pays attention.
- Reinforce your income base by scanning 8 dividend fortresses that focus on higher yields backed by stronger fundamentals.
- Strengthen your downside protection by filtering for 31 resilient stocks with low risk scores so you are not caught off guard when volatility picks up again.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com